Inhaled antibiotic formulations represent one of the most promising avenues for overcoming antibacterial drug resistance. This is achieved by delivering high local doses of antibiotics directly to infected cells, which specifically targets biofilm/mucus and resistant pathogens. Although promising developments of inhaled antibacterials include proteins and peptides, liposomal and lipid‑based nano-carriers, combination therapies, phase therapy, alveolar macrophage targeted delivery are progressing, some potential barriers such as mucus, biofilms, and bacterial resistance continue to impede clinical translation. As a result, real-world strategic priorities should be emphasized regarding the development of smart inhaled antibacterial formulations with clinical potential to overcome the ongoing barriers associated with antimicrobial-resistant bacteria.
Islam et al. (Tue,) studied this question.